FOLH1 and neoplasm: In preclinical models, CB307 augmented tumor cell killing in PSMA-expressing cells, and enhanced tumor cell cytotoxicity were observed when in combination with PD-1/PD-L1 inhibition.87 A phase I study (NCT04839991) is currently investigating the safety and efficacy of CB307 both as monotherapy and in combination with pembrolizumab in patients with advanced and/or metastatic PSMA-positive tumors including mCRPC.